Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
WKECSELYDBZHQV
|
8.7 | IC50 | 5 | — | |
DAACIVVJMPRYNY
|
8.7 | IC50 | 2 | — | |
OJHZGOVZQFYDCL
|
8.7 | IC50 | 2 | — | |
XVJNXINQULRUSZ
|
8.7 | IC50 | 2 | — | |
ZELSVXRHOIURQO
|
8.7 | IC50 | 2 | — | |
BWAPBAYGNOERHW
|
8.6 | IC50 | 3 | — | |
DPJBHUNXNGXHKX
|
8.6 | IC50 | 2 | — | |
JVZAZERWGBCCMA
|
8.6 | IC50 | 2 | — | |
KQOPZHLMVMXEBU
|
8.6 | IC50 | 2 | — | |
OYNVIRWWJGTUHL
|
8.6 | pIC50 | 3 | Yes | |
WUPAMXPGAGXOBC
|
8.6 | IC50 | 2 | — | |
XDXZHIQVJAQRGY
|
8.6 | IC50 | 5 | — | |
XQLUKUIXLCBLHW
|
8.6 | Ki | 2 | — | |
NQLVCSKRIFKMMQ
|
8.6 | Ki | 2 | — | |
PLQOKDSGXCSTPR
|
8.6 | IC50 | 2 | — | |
QVKXSOFEMBBXIZ
|
8.6 | IC50 | 2 | — | |
TXQHNXLSHVFBCJ
|
8.6 | Ki | 2 | — | |
WMUSVQYISLQOOI
|
8.6 | IC50 | 2 | — | |
PPSXOMUYKRJEAG
|
8.6 | IC50 | 2 | — | |
VIQZNMLBVAPZSJ
|
8.6 | IC50 | 2 | — | |
AICMEPHIKCWYDQ
|
8.6 | Ki | 3 | — | |
AINIBIDPBURRQT
|
8.6 | IC50 | 2 | — | |
BBAADHSKLBRJIT
|
8.6 | IC50 | 2 | — | |
DJDMOZPHORDJAO
|
8.6 | IC50 | 2 | — | |
HRRNDHFMTPCCMO
|
8.6 | IC50 | 3 | — | |
NPQPJCWZDJSQHJ
|
8.6 | IC50 | 2 | — | |
OIOOKLQHEDGJOE
|
8.6 | IC50 | 3 | — | |
QDMLWRQDYNWDNC
|
8.6 | Ki | 2 | — | |
YSXQXPGHVPLVAX
|
8.6 | IC50 | 2 | — | |
DJVVXKDLVNGSNI
|
8.6 | IC50 | 2 | — | |
KQSIJQWEUOVQTK
|
8.6 | IC50 | 3 | — | |
QSWOZMQJOSGBIB
|
8.6 | IC50 | 2 | — | |
YEQTWRJYERBWFH
|
8.6 | IC50 | 2 | — | |
GOWCQHQTMSIPRR
|
8.6 | IC50 | 3 | — | |
JBCFMJUKWOMHEO
|
8.6 | IC50 | 6 | — | |
PDASOYUSMAATLD
|
8.6 | IC50 | 2 | — | |
YVXILUOSLZRLOG
|
8.6 | Ki | 2 | — | |
HWYQOUOQSBJDQJ
|
8.6 | IC50 | 2 | — | |
JQQOPLRIUXGXLO
|
8.6 | IC50 | 2 | — | |
LUEQFYIKOIQERT
|
8.6 | IC50 | 2 | — | |
NIHHQWZEUOCDGK
|
8.6 | IC50 | 2 | — | |
NNBQPBRMABHXMF
|
8.6 | IC50 | 2 | — | |
QOXUQJROGWQVGY
|
8.6 | IC50 | 2 | — | |
QRYDPOHAXNITJN
|
8.6 | IC50 | 3 | — | |
RMDMQRLDXOVESD
|
8.6 | IC50 | 2 | — | |
WKXLDCTVVNFJRQ
|
8.6 | IC50 | 2 | — | |
COLNITJAPAQHCQ
|
8.6 | IC50 | 3 | — | |
QAQNRPZNOFLCEK
|
8.6 | IC50 | 2 | — | |
WFKMYKMRKJBXKM
|
8.6 | IC50 | 2 | — | |
XKPJYTLNNLDKQP
|
8.6 | IC50 | 2 | — |